<DOC>
	<DOCNO>NCT02213146</DOCNO>
	<brief_summary>The addition BioChaperone already market prandial human insulin preparation may accelerate onset shorten duration action due facilitation insulin absorption subcutaneous injection . The aim trial ass efficacy safety BioChaperone human insulin subject type 1 diabetes dose 0.2 U/kg . This trial single center , randomise , double-blinded , three treatment , three-period cross-over , 10-hour euglycaemic clamp trial subject type 1 diabetes mellitus . Each subject randomly allocate single dose BioChaperone human insulin 0.2 U/kg , single dose Huminsulin® Normal 0.2 U/kg single dose Humalog® 0.2 U/kg 3 separate dose visit .</brief_summary>
	<brief_title>A Double-blinded , Randomised , Three-period Crossover Euglycaemic Clamp Trial Investigating Pharmacokinetics , Glucodynamics Safety BioChaperone Human Insulin , Human Insulin ( Huminsulin® Normal ) Insulin Lispro ( Humalog® ) Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Male subject type 1 diabetes least 12 month Treated multiple daily insulin injection insulin pump ( CSII ) least 12 month Body mass index : 18.528.0 kg BW·m2 HbA1c : ≤ 9.0 % Diabetes mellitus type 2 Receipt investigational product within 3 month prior first dose investigational product trial Clinically significant abnormality judge Investigator Any systemic treatment drug know interfere glucose metabolism History alcoholism drug/chemical abuse per Investigator 's judgement Use tobacco nicotinecontained product within one year prior screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>